Wird geladen...

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms

Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly. Ruxolitinib is the first clinically useful targeted therapy in Philadelphia chromosome-negative myeloproliferative neopla...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Turk J Haematol
Hauptverfasser: Eliaçık, Eylem, Işık, Ayşe, Aksu, Salih, Üner, Ayşegül, Büyükaşık, Yahya, Sayınalp, Nilgün, Göker, Hakan, Özcebe, Osman İ., Haznedaroğlu, İbrahim C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Galenos Publishing 2015
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4451485/
https://ncbi.nlm.nih.gov/pubmed/26316485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4274/tjh.2013.0265
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!